EGFR and neoplasm: Broad-spectrum Gln metabolic antagonists can inhibit the uptake and utilization of Gln by tumor cells, thereby suppressing tumor cell proliferation and increasing sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC (26).